Related Experiment Video

Updated: May 22, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Monoclonal TCR-redirected tumor cell killing

Nathaniel Liddy1, Giovanna Bossi, Katherine J Adams

  • 1Immunocore Ltd., Abingdon, Oxon, UK.

Nature Medicine
|May 8, 2012
PubMed

Insights

New immune-mobilizing monoclonal TCRs against cancer (ImmTACs) redirect T cells to effectively target and eliminate cancer cells, even those with low antigen levels. This breakthrough overcomes immune tolerance, offering a novel cancer immunotherapy approach.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • T cell immunity shows potential in eradicating cancer cells, but many patients experience T cell receptor (TCR)-mediated recognition failure.
  • Existing immunotherapies face challenges in overcoming cancer's immune tolerance.
  • Targeting tumor-associated antigens is crucial for effective cancer immunotherapy.

Purpose of the Study:

  • To engineer and characterize novel reagents, termed immune-mobilizing monoclonal TCRs against cancer (ImmTACs).
  • To evaluate the efficacy of ImmTACs in redirecting T cells against cancer cells, including those with low antigen expression.
  • To assess the potential of ImmTACs as a new therapeutic strategy for cancer immunotherapy.

Main Methods:

  • Engineering of ImmTACs by fusing tumor-associated epitope-specific monoclonal TCRs with CD3-specific single-chain antibody fragments (scFvs).
  • Characterization of four distinct ImmTAC reagents with picomolar affinity.
  • In vitro assessment of T cell redirection and cancer cell killing.
  • In vivo studies to evaluate tumor growth suppression.

Main Results:

  • Engineered ImmTACs effectively redirected T cells to kill cancer cells expressing extremely low surface epitope densities.
  • Four distinct ImmTACs demonstrated potent tumor growth suppression in vivo.
  • ImmTACs showed high affinity for tumor-associated epitopes, enabling precise T cell activation.

Conclusions:

  • ImmTACs represent a novel class of reagents for cancer immunotherapy.
  • These engineered molecules overcome immune tolerance, enhancing T cell-mediated cancer cell elimination.
  • ImmTACs offer a promising new approach to treating cancer by improving T cell recognition and activation.

More Related Videos

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...